. . . . "investigational"@en . "8.4-19.3 hrs"@en . . . . "approved"@en . "Antihemophilic Factor"@en . . . . . . . . . . . . . . . . . "* 4.1 mL/h\u2022kg [Previously treated pediatric patients]"@en . . . "# Titheradge MA, Coore HG: Initial rates of pyruvate transport in mitochondria determined by an \"inhibitor-stop\" technique. Biochem J. 1975 Sep;150(3):553-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2157"@en . " "@en . . "Humans and other mammals"@en . "Factor VIII"@en . "For the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency."@en . "James W. Bloom, \"Warm ethanol method for preparation of low fibrinogen antihemophilic factor.\" U.S. Patent US4478825, issued June, 1955."@en . . . . . . . . "Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells"@en . . . . . . . . . . . . . . . . . . . . . "AHF"@en . . . . . . . . . "Antihemophilic factor (AHF) is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A (classical hemophilia)."@en . . . . . . . . . . . . .